PDCD1 and cancer: A major limitation of anti–PD-1/anti–PD-L1 mAbs is their inability to distinguish PD-1–PD-L1 interactions in the TME, which prevent effective cancer immunity, from PD-1–PD-L1 interactions in normal tissues, which protect against autoimmune diseases.